Overview

Health care cost to society has risen to levels which are no longer sustainable.

This fund invests globally in innovative companies which are driving a revolution in the health care sector through the application of technology.

The investment universe comprises three segments: Research & Development, Treatments and Efficiency. The fund invests in “pure-play” digital health companies, which are typically small to mid-sized.

The portfolio manager is not tied to the benchmark in terms of investment selection or weight.

Benefits

Offers diversified exposure to the digital health universe, which is one of the fastest growing segments in the health care industry.

The investment objective is long-term capital appreciation from actively managed exposure to this secular growth theme.

Risks

麻豆社 Thematic Funds invest in equities and may therefore be subject to high fluctuations in value. As these 麻豆社 Funds pursue an active to very active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on specifict themes and trends may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk). This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class. Sustainability risks are environmental, social or governance events or conditions that can have a material negative effect on the return, depending on the relevant sector, industry and company exposure. Sustainability risk: the risk arising from any environmental, social or governance events or conditions that, were they to occur, could cause a material negative impact on the value of the investment.

Features

Product category
麻豆社 Thematic Funds
Product domicile
Luxembourg
Portfolio management
麻豆社 Asset Management (Americas) LLC, New York
Fund management
麻豆社 Asset Management (Europe) S.A., Luxembourg
Custodian bank
麻豆社 Europe SE, Luxembourg Branch
Representative for products established under foreign law
麻豆社 Asset Management (UK) Limited
Day of inception
15 December 2020
Currency of account
GBP
Close of financial year
31 May
SFDR Classification
Art.8
Issue / redemption
daily
Distribution
Reinvestment
Maturity
Open end
Ongoing costs p.a.
0.86% p.a.
Management fee
0.61% p.a.
Minimum investment
n.a.
Reference Index / Benchmark
MSCI AC World (NR) (GBP hedged)
ISIN
LU2267085962
Bloomberg Ticker
CSDHXBH LX
Reuters Id
58679705X.CHE

Performance and Prices

Percentage growth

as of 18 June 2026
Cumulative
GBP(%) EUR(%)
YTD
1M
3M 3.92 3.62
6M -5.45 -4.50
1Y 4.59 3.23
2Y 7.10 4.56
3Y -10.31 -11.76
5Y
ø p.a.5Y -11.94 -12.10
Discrete Annual
GBP(%) EUR(%)
Q1 2025 to Q1 2026 6.37 1.88
Q1 2024 to Q1 2025 -13.96 -12.10
Q1 2023 to Q1 2024 3.23 6.10
Q1 2022 to Q1 2023 -19.63 -22.70
Q1 2021 to Q1 2022 -30.76 -30.20

Current data

Net asset value 18.06.2026 GBP 54.28
High - last 12 months 07.01.2026 GBP 60.71
Low - last 12 months 30.03.2026 GBP 49.54
Assets of the unit class in mn 17.06.2026 GBP 0.33
Total product assets in mn 17.06.2026 GBP 329.86

Structures

By the 10 largest positions (in %, as of 29 May 2026)

 
 
Guardant Health Inc 4.27
Intuitive Surgical Inc 3.14
Arrowhead Pharmaceuticals Inc 3.05
Koninklijke Philips NV 2.86
IRhythm Holdings Inc 2.81
Natera Inc 2.73
Ionis Pharmaceuticals Inc 2.71
Alcon AG 2.71
Denali Therapeutics Inc 2.70
Dexcom Inc 2.69

Fees

Ongoing costs p.a.
0.86%
Flat fee
n.a.
Management fee p.a.
0.61%
Max. issuing commission
5.00%
Max. redemption commission
0.00%
Distribution fee
(see info)

Distributions

No distributions. Continuous reinvestment of income.

Sales Authorisations

Market
Sales authorisations status
Australia
Institutional Only*
Austria
Registered
Costa Rica
Institutional Only*
France
Registered
Germany
Registered
Italy
Registered
Luxembourg
Registered
Netherlands
Registered
Singapore
Institutional Only*
Spain
Registered
Switzerland
Registered
United Kingdom
Registered

Literature

Brochures
Document type
Document Language
Fact Sheet
Manager Commentary
Fact Sheet - 麻豆社 Thematic Funds
Agreement / Prospectus
Document type
Document Language
Prospectus
Country supplement
Key Investor Information (KIID)
Annual and semi-annual report (accounting on 31 May)
Document type
Document Language
Annual report
Semi-annual report
Please wait for the requested content to load. If there is no response after several minutes, please reload the page or try again later.

We’re here to help

Contact us

For general inquiries with 麻豆社 Asset Management, fill in a form with your details and we’ll be back in touch.

Our leadership team

Our global leadership team is deep, diverse, and dedicated to our ethos of delivering investment excellence.

Find your local 麻豆社 office

As your expert global partner, we're closer than you think. Discover 麻豆社's locations in your region.